GW Pharmaceutical Archives

William SumnerAugust 7, 2018

The London-based pharmaceutical company, GW Pharmaceuticals (GWPH), today announced the release of its financial results for the quarter ending on June 30, 2018. During the last quarter, the company earned FDA approval for its cannabis-based drug Epidiolex in the treatment of seizures associated with LGS or Dravet syndrome. The company expects the FDA to reschedule […]

StaffAugust 7, 2018

It’s time for your Daily Hit of cannabis financial news for August 7, 2018. On The Site: Aurora Cannabis Inc. Aurora Cannabis Inc. (ACBFF) today announced that it has entered into a letter of intent to acquire HotHouse Consulting Inc. Founded in 2004, HotHouse provides greenhouse consulting services and specializes in hybrid greenhouse growing techniques. Initially, the company focused primarily […]

Debra BorchardtJune 25, 2018

It’s time for your Daily Hit of financial cannabis news for June 25, 2018. On The Site GW Pharmaceuticals If any other company released any news today, then it went basically unnoticed because the FDA approved GW Pharmaceutical’s (GWPH) cannabidiol drug Epidiolex. The news was expected sometime this week, so it was nice of the FDA […]

Debra BorchardtJune 25, 2018

The U.S. Food and Drug Administration (FDA) approved GW Pharmaceuticals’ (GWPH) cannabidiol (CBD) drug Epidiolex as an oral solution for the treatment of seizures associated with two rare and severe forms of epilepsy, Lennox-Gastaut syndrome, and Dravet syndrome, in patients two years of age and older. According to the press release, this is the first FDA-approved […]

William SumnerMay 17, 2018

The biopharmaceutical company GW Pharmaceuticals (GWPH), along with its U.S. subsidiary Greenwich Biosciences, announced the publication of its Phase 3 study of cannabidiol oral solution in patients with Lennox-Gastaut syndrome (LGS) in The New England Journal of Medicine. Announcing positive results, GW CEO Justin Gover hailed the study’s publication as another landmark moment for the […]

Video StaffApril 20, 2018

Happy 4/20 everyone. It’s the day the cannabis industry likes to celebrate as their special holiday. It’s become a huge business deal for the industry. A recent study done by LeafLink predicts that this 4/20 will be the first ever to have retail sales top $1B, even reaching as high as $1.2B, based on their wholesale marketplace figures. According […]

Debra BorchardtApril 19, 2018

GW Pharmaceuticals Inc. (GWPH) continues to get closer and closer to FDA approval of its drug Epidiolex for the rare forms of epilepsy Lennox-Gastaut and Dravet Syndrome. Epidiolex is GW’s lead cannabinoid product candidate and is a pharmaceutical formulation of purified cannabidiol or CBD. Following a live hearing on Thursday, the company announced that the Peripheral and […]

Debra BorchardtFebruary 5, 2018

epidiolex-cannabidiol-or-cbd-bottle-and-packaging-1280x853.jpg

GW Pharmaceuticals (GWPH) saw its stock slip in after-hours trading after the UK-based biotech company reported its first-quarter earnings and positive news out of Europe. First, revenue for the first quarter rose 203% to $7.7 million beating estimates by $5.4 million and topping last year’s revenue for the same period. However, losses increased to $63.3 million […]

Debra BorchardtDecember 5, 2017

GW Pharmaceuticals (GWPH) fell almost 4% in after-hours trading after the British biotech company said it would sell $225 million of American Depositary Shares (ADSs) on the NASDAQ exchange in an underwritten U.S. public offering. GW expects to grant the underwriters a 30-day option to purchase up to an additional $33.75 million of ADSs at the […]

Debra BorchardtDecember 4, 2017

London-based biotech company GW Pharmaceuticals (GWPH) reported its fourth quarter and fiscal year-end results with revenues dipping and losses rising as the company gets closer to launching its Epidiolex drug in the U.S. GW Pharmaceuticals delivered revenue of $11 million or 8.2 million in sterling pounds for the year ending September 30. This was lower […]

Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC

Functional Mushrooms Move Into Mainstream as Wellness Trend Grows

In other news

The Daily Hit: January 4, 2024

Connecticut Attorney General Tells Unlicensed Cannabis Events Company to Stop

Testing Concerns Lead to Quarantine for 70% of Mississippi MMJ Goods

Tag: GW Pharmaceutical

GW Pharmaceuticals Releases Financial Results for the Third Quarter

The Daily Hit: August 7, 2018

The Daily Hit: June 25, 2018

FDA Approves GW Pharmaceutical’s Cannabis Drug Epidiolex, Rescheduling Expected In 90 Days

Positive Results From Epidiolex Study Sends GW Pharmaceuticals Stock to All Time High

Marijuana Money April 20, 2018

Panel Recommends Approval Of GW Pharmaceutical Cannabis Drug For Epilepsy

GW Pharmaceuticals Revenue Jumps Over 200% In First Quarter

GW Pharma Stock Falls After Announcing Offering

GW Pharmaceuticals Says 2018 ‘A Pivotal Year’

The Daily Hit - TEST TEST TEST

Lykos Therapeutics Secures $100M in Series A Funding, Rebrands from MAPS PBC

Functional Mushrooms Move Into Mainstream as Wellness Trend Grows

Get the latest cannabis news delivered right to your inbox

Get the latest cannabis news delivered right to your inbox